MDA-MB Transfection Reagent (Breast Adenocarcinoma)
Transfection Reagent for MDA-MB Cells (Breast Adenocarcinoma Cells, HTB-26)
Optimized for MDA-MB-231, MDA-MB-435, MDA-MB-468 cell lines
Two component formulation enhances lipid mediated transfection efficiency
Optimized easy-to-use transfection protocol provided for transfection of siRNA, DNA, mRNA, and microRNA
Kit includes Transfection Enhancer reagent and recommended transfection protocol
High transfection efficacy in the presence of serum
Expand your RNAi application with a reagent optimized for delivery of both siRNA and plasmid
Reproducible transfection results
Works well for standard reverse transfection and high-throughput applications
Developed and manufactured by Altogen Biosystems
Reagent exhibits at least 80% transfection efficiency of siRNA delivery. Transfection efficiency was determined by qRT-PCR.
Transfection Protocol and MSDS:
Download Altogen Biosystems MDA-MB Transfection Protocol: [PDF]
Download MSDS: [PDF]
MDA-MB Cell Lines:
MDA-MB-453 cells were derived in 1976 from an effusion of a 48-year old Caucasian woman with metastatic carcinoma of the breast, involving the nodes, brain and both pleural and pericardial cavities. Certain MDA-MB cell lines are not tumorigenic in immunosuppressed mice, but do form colonies in semisolid medium. The cells— epithelial-like, round, loosely attached monolayers— overexpress FGF receptors. It has been found that stimulation of MDA-MB-453 cells with HRG beta 2 resulted in the tyrosine phosphorylation of p185c-erbB-2 and p180erbB-4 in a time and dose dependent way. MDA-MB-453 cells also have an active glycerol 3-phosphate shuttle. MDA-MB-453 cells express high levels of functional androgen receptor, providing a valuable in vitro model for further studies on androgen regulation of gene expression, and possibly cell proliferation, in breast cancer. MDA-MB-453 cells were use to determine that G-protein-coupled inwardly rectifying potassium (GIRK) are involved in cellular signaling exist in breast cancer cells. There are several different cell lines, many of which who possess different characteristics, in the MDA-MB category, including MDA-MB-231, MDA-MB-435, and MDA-MB-468.
Figure 1. Cyclophilin B silencing efficiency was determined by qRT-PCR in the MDA-MB-453 cells transfected by Cyclophilin B siRNA or non-silencing siRNA control following the recommended transfection protocol. Cyclophilin mRNA expression levels were measured 48 hours post-transfection. 18S rRNA levels were used to normalize the Cyclophilin B data. Values are normalized to untreated sample. Data are presented as means ± SD (n=3).
Altogen Biosystems is a life sciences company that offers cell type-specific and pre-optimized transfection products, elecroporation kits, and in vivo delivery reagents (peg-liposome, nanoparticle, lipid, and polymer-based; and tissue targeted: liver, pancreas, kidney). Advanced formulation of reagents and optimized transfection protocols provide efficient intracellular delivery of protein, DNA, mRNA, shRNA and siRNA molecules. Read more about transfection technology at Altogen's Transfection Resource.
Altogen Research Services:
Altogen Labs is a GLP compliant laboratory that provides preclinical contract research services (CRO). Pharma and biotechnology services include: transient and stable transfection (development of stable cell lines), liposome encapsulation (proteins, DNA, mRNA, siRNA), A-to-Z RNAi services, in vivo and in vitro toxicology, xenograft animal models, assay development, cell banking and cryopreservation services.